Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Boehringer Ingelheim
Dow
AstraZeneca
Harvard Business School

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SGN-CD19A


Email this page to a colleague

« Back to Dashboard

Clinical Trials for SGN-CD19A

Trial ID Title Status Sponsor Phase Summary
NCT00028483 ↗ Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer Terminated Seagen Inc. Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and monoclonal antibody therapy in treating women who have metastatic or recurrent breast cancer.
NCT00028483 ↗ Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer Terminated Seattle Genetics, Inc. Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and monoclonal antibody therapy in treating women who have metastatic or recurrent breast cancer.
NCT00031187 ↗ Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer Completed Seagen Inc. Phase 2 SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.
NCT00031187 ↗ Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer Completed Seattle Genetics, Inc. Phase 2 SGN-15 is being investigated for therapy of patients with prostate cancer in combination with the cytotoxic agent, Taxotere. The study is an open label, randomized phase II study for patients with documented hormone refractory prostate cancer who have not had any prior therapy with Taxotere or Novantrone. Both SGN-15 and Taxotere will be administered weekly over two 6 week courses separated by a 2 week rest period.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for SGN-CD19A

Condition Name

Condition Name for
Intervention Trials
Lymphoma, Non-Hodgkin 11
Acute Myeloid Leukemia 7
Disease, Hodgkin 7
Lymphoma, Large-Cell, Anaplastic 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Lymphoma 43
Hodgkin Disease 19
Lymphoma, Non-Hodgkin 19
Lymphoma, Large-Cell, Anaplastic 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SGN-CD19A

Trials by Country

Trials by Country for
Location Trials
United States 617
Italy 16
Spain 15
Canada 13
France 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 46
New York 43
Texas 43
Alabama 33
Washington 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SGN-CD19A

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 4
Phase 2 27
Phase 1/Phase 2 11
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 39
Terminated 19
Active, not recruiting 9
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SGN-CD19A

Sponsor Name

Sponsor Name for
Sponsor Trials
Seagen Inc. 63
Seattle Genetics, Inc. 59
Millennium Pharmaceuticals, Inc. 10
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 145
Other 19
NIH 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Johnson and Johnson
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.